Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...

Subcutaneous pembrolizumab with berahyaluronidase alfa is FDA-approved for all solid tumor indications, including metastatic nonsquamous NSCLC. The phase 3 3475A-D77 trial confirmed noninferior ...

THURSDAY, July 31, 2025 (HealthDay News) -- Intranasal administration of [68 Ga]Ga-NOTA-insulin is safe and delivers insulin to multiple brain regions, according to a study published online July 23 in ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

Pucotenlimab in high microsatellite instability/mismatch repair–defificient (MSI-H/ dMMR) solid tumors: Results update from a multicenter, phase II, open-label study. This is an ASCO Meeting Abstract ...

We would like to present four cases in which we have successfully administered a short subcutaneous infusion of omeprazole, not previously demonstrated in the literature. A woman in her early 60s was ...

Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert. The subcutaneous formulation of daratumumab (Darzalex), known ...

For patients with metastatic non–small cell lung cancer (NSCLC), subcutaneous (SC) administration of pembrolizumab works just as well as standard intravenous (IV) administration, phase 3 data ...

Merck has shared data from the pivotal 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa (subcutaneous pembrolizumab). The study ...